Parkinson’s is becoming younger Reports show that about 10% of the total number of Parkinson’s disease patients under 40 years old in China. Ten years ago the age of onset of Parkinson’s disease is generally above 55 years old, but in recent years some patients are as young as 23 or 24 years old, which may be related to environmental pollution, electromagnetic radiation, etc. A recent epidemiological survey confirmed that the proportion of intellectuals suffering from Parkinson’s disease is indeed higher than the rest of the population, which may be mainly due to long-term stressful working conditions and high mental stress. The exact cause of the disease and the cure are still under study. Smoking to prevent Parkinson’s is not credible Smoking to prevent Parkinson’s? Patients with Parkinson’s disease should have the concept of lifelong treatment. Although fewer long-term smokers have Parkinson’s disease than nonsmokers, it should not be assumed that smoking prevents the onset or progression of Parkinson’s disease. Smoking is a major risk factor for respiratory and cardiovascular disease, he said, and the benefits of smoking in reducing the incidence of Parkinson’s disease seem insignificant compared to the other harms of smoking. Half of the patients give up treatment The incidence of Parkinson’s disease in China is now close to that of Western countries, with a prevalence rate of 1 percent among people over 55 years of age, and 100,000 new patients will be added each year. In Guangzhou, the total number of Parkinson’s patients exceeds 10,000, yet 50% of patients give up treatment. Many people believe that it is irreversible and that no amount of treatment will help. Although there is no cure, early and aggressive treatment can effectively control the disease. There are many patients who can completely achieve self-care after taking medication. Second, the cost of treating Parkinson’s disease is relatively not very high. The average patient only needs to spend about $300 per month through medication, and only $20,000 for cytoblade surgery. Some studies have shown that for treating patients with advanced disease the cost is three to five times more expensive than for early to mid-stage patients.